South Bend Medical Foundation - Your Community Laboratory

test directorySearch Results

Click here to search again.

Test Name:
Neuronal IgG Antibodies (Hu, Ri, Yo, Amphiphysin), by Immunoblot

• SBMF No:
  44513
• Performance Lab Name:
  ARUP Laboratories
• Test Mnemonic:
  NEURONALIB
• ABN:
  Required – Not FDA-Approved
• CPT Code:
  83516
• LOINC Code:
  12853-8; 35278-1; 33008-4
• Ref Lab Test No:
  0051090
• Test Includes:
  ANNA-1 (anti-Hu)
  ANNA-2 (anti-Ri)
  PCCA or PCA-1 (anti-Yo)
  Amphiphysin IgG Antibodies
• Also Known As:
  ANNA-1 (Anti-Hu), ANNA-2 (Anti-Ri), and PCCA or PCA-1 (Anti-Yo)
• Also See:
  44512 Neuronal Nuclear IgG Antibodies (Hu and Ri), by Immunoblot
• Spec Type:
  Serum
• Spec Container:
  Gold top (SST) or red top (serum) tube
• Pref Vol:
  1.0 mL
• Min Vol:
  0.5 mL
• Fasting:
  No
• Spec Collect:
  Routine venipuncture
• Spec Process:
  Clot 30 minutes
  Promptly centrifuge 15 minutes
  Immediately transfer serum to separate plastic tube and freeze
• Spec Store Transport:
  Frozen
• Spec Stability:
  After separation from cells:
  24 hours room temperature (20-30°C)
  2 weeks refrigerated (-2-8°C)
  1 year frozen (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles
• Spec Reject:
  Plasma sample
  Lipemic, hemolyzed, contaminated, or heat-inactivated sample
• Spec Remarks:
  Separate serum from cells ASAP
• Methodology:
  Immunoblot
• Clinical Significance:
  Refer to:
  
• Reference Range:
  

  Neuronal IgG Antibody, Immunoblot Anti-Hu
  Negative

  Neuronal IgG Antibody, Immunoblot Anti-Ri
  Negative

  Neuronal IgG Antibody, Immunoblot Anti-Yo
  Negative

  Neuronal IgG Antibody, Immunoblot Amphiphysin
  Negative

  Interpretive Data:
  Anti-Hu, type I anti-neuronal nuclear (ANNA-1) is associated with small cell lung cancer. Anti-Ri, type II anti-neuronal nuclear (ANNA-2) is associated with neuroblastoma (children) and fallopian tube or breast cancer (adults). Anti-Yo, anti-purkinje cell cytoplasmic antibodies (PCCA or PCA-1) is associated with ovarian and breast carcinomas.

  The presence of one or more of these antibodies supports the clinical diagnosis of paraneoplastic syndrome and leads to a focused search for underlying neoplasm. These markers aid in the discrimination between true paraneoplastic disorders and other inflammatory disorders of the nervous system.

  Amphiphysin antibodies are present in about 5% of patients with stiff person syndrome and variably in other paraneoplastic neurological syndrome (PNS) cases. Amphiphysin antibodies are mostly associated with samll cel lung cancer (SCLC) and breast tumors.

• Additional Test Info:
  This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
• Day Run:
  Thu
• Time Reported:
  2-9 days
• Test Type:
  IMMUNOLOGY